Cell and Gene Therapy Sector Further Advised to Go Digital

Published on :

Luke Thorstenson, director of business development at cell and gene therapy and production technology firm Orgenesis, also says digitized manufacturing is key to production scaleup.
“A significant challenge in the production of pharma and biotech products is the automation and integration of individual manufacturing operations,” he tells GEN. “Transitioning from the current ‘analog’ labor-intensive manufacturing process to machine automated processes like those in our Orgenesis Mobile Processing Units and Labs (OMPULs) requires digitization and will allow for the same activities currently done manually by an operator to efficiently scale. We believe these steps are necessary to make life saving treatments like CAR-T available, accessible and affordable.”

In Conversation with Kevin Hannigan, President of Lab Owl®/Automated Control Concepts, Inc.

Published on :

Personalized and regenerative medicines are promising but they are complex to develop and require highly-flexible advanced manufacturing techniques that are still too manually intensive and costly.